The FTC's Beef with Pay For Delay: What's the Fuss?
Yesterday, the Supreme Court heard arguments on the matter of pay-for-delay settlements between patent holders and generic firms. The Federal Trade Commission (FTC) hopes to overturn the 11th federal...
View ArticleClik here to view.
FTC v. Actavis: Supreme Court Decision—The Rule of “No” Reason
by Traci Medford-Rosow and Peter Richardson On June 17, 2013 the Supreme Court decided FTC v. Actavis by a 5-3 vote. Justice Breyer delivered the majority opinion with Justices Kennedy, Ginsburg,...
View ArticleFTC vs Actavis: Patent Settlements Become More Risky
Pharmaceutical companies can anticipate more costly, drawn-out patent litigation in the wake of the June 17 US Supreme Court decision, which creates great uncertainty about the grounds for negotiating...
View ArticleActavis to Acquire Forest Labs for $25 Billion
Actavis and Forest Laboratories have entered into a definitive agreement under which Actavis will acquire Forest for a combination of cash and equity valued at approximately $25 billion or $89.48 per...
View ArticleActavis Marches Ahead with Acquisition Spree
Actavis’s agreed purchase of Allergan for around $66 billion will help grow the Dublin-based specialty pharma firm to a $22 billion healthcare company in 2015 — a “dramatic elevation”, given the $8.7...
View Article
